Press & News

The next generation biopharmaceuticals

Press releases

2019-02-20

Affibody Completes Enrollment in Phase 2 Psoriasis Trial of ABY-035

Solna, Sweden, February 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of enrollment in the Company’s Phase 2 proof-of-concept study of ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”).[read more]

Older press releases

2018-12-04

Affibody Announces Option Exercise by Biotest

Solna, Sweden, December 4, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that its partner Biotest, a Germany-based biotherapeutic company, has exercised an option under the two companies’ ongoing...[read more]

2018-11-16

Interim Report – January to September 2018

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter 2018. Financial Highlights...[read more]

2018-09-24

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that a major Nordic study (“Affibody-3”) will begin using Affibody’s PET imaging agent ABY-025.[read more]

Affibodys latest Press releases

2019-03-28

Interview with Affibody’s CEO (in Swedish)

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q1 (May 17, 2019)

Investor information